Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cadherin 12 pseudogene 4 is classified as a pseudogene. Pseudogenes are genomic DNA sequences similar to normal genes but non-functional, usually due to mutations that disable their coding or regulatory sequences[2][6][4]. As a pseudogene, CDH12P4 does not encode a functional protein and is not considered a therapeutic target. Pseudogenes can sometimes participate in gene regulation (for example, by acting as competing endogenous RNAs or generating regulatory RNAs), but most do not have a well-characterized biological function, and there is no evidence in the literature that CDH12P4 is functional or related to disease. Its closest functional relative is cadherin 12 (CDH12), a classical cadherin involved in neural development and cancer progression[1][5][7], but CDH12P4 itself is a defunct gene segment and not a protein-coding or receptor target. Detailed context and explanation: - Is_target: A therapeutic target is usually a functional gene product (protein, such as a receptor, enzyme, transporter, etc.) that can be modulated by drugs. Pseudogenes, by definition, are not translated into functional proteins and thus are not conventional therapeutic targets[2][4]. - Is_incorrect: There is something technically "incorrect" or misleading about using CDH12P4 as a drug target; it is not a gene product that can be targeted by small molecules, antibodies, or other therapies. It may be indexed in bioinformatics databases because of sequence similarity to CDH12, but any reference to CDH12P4 as a receptor or drug target is erroneous. - Molecular classification: Pseudogenes are a distinct molecular class (sometimes grouped as "other" or "regulatory RNA" if expression is detected), but they are not functional receptors, enzymes, and so on[2][4][6]. - Biological/disease functions: CDH12 (the parent gene) plays key roles in neuronal development, adhesion, and cancer progression[1][5][7]. However, most pseudogenes, including CDH12P4, are biologically inert, though some pseudogenes can potentially regulate parent genes via RNA processes[2][4][8]. No such activity is known or described for CDH12P4. - Aliases: Alternative names reflect convention in genomics, but none point to a functional role. - Interacting drugs, mechanisms of action, biomarkers, safety concerns: None are described or expected for CDH12P4, as it produces no protein product and is not a functional molecule[2][4][6][8]. Summary: Cadherin 12 pseudogene 4 (CDH12P4) is a non-functional, pseudogenic DNA sequence related to the cadherin family, specifically cadherin 12, but does not encode a protein or serve any confirmed functional or therapeutic role[2][4][6]. Any use as a drug target or receptor is incorrect and unsupported by current molecular biology knowledge.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cadherin 12 pseudogene 4 (CDH12P4).